Tuesday, March 22, 2022

Neurana Pharmaceuticals Looks For Buyer After Failure Of Phase 3 Study

San Diego-based biotechnology company Neurana Pharmaceuticals says it is looking for "strategic alternatives", following failure of its Phase 3 clinical trials. According to Neurana, the clinical study of its compound, tolperisone, for the relief of muscle spasm associated with acute, painful musculoskeletal conditions, failed to meet its primary and key secondary endpoints. The company said the "efficacy of tolperisone did not demonstrate significance as compared to placebo." The company said it has "reduced" its employee headcount and spending, and if no strategic alternatives are identified, it will "begin a plan of dissolution."

---